Joint research program between the Japan Agency for Medical Research and Development and the Canadian Institutes of Health Research focuses on advancing technologies in epigenomics, deepening McGill’s relationship with Japan’s RIKEN institute.
By Junji Nishihata
Dr. Reza Alizadehfar, Associate Professor in the Division of Allergy, Immunology and Dermatology in the Department of Pediatrics, on receiving the national prestigious John Toogood Teaching Award from the Canadian Society of Allergy and Clinical Immunology (CSACI).
The John Toogood Teaching Award is presented to a CSACI member in recognition of his or her exemplary teaching in the field of Allergy, Asthma, and Immunology. To be considered for this award, the candidate should be actively involved in teaching trainees and demonstrate excellence in teaching and mentoring.
Understanding how bats cope with viruses could help us develop COVID-19 therapies, according to this article in Knowable Magazine. One of our faculty members, Dr. Judith Mandl, was interviewed for the article and is currently studying the immune response of bats in her lab.
Dr. Adrian Dancea has been appointed to a third and final mandate as Division Director of Pediatric Cardiology with the term to commence on July 1, 2020.
A medical graduate of the University of Ottawa, Dr. Dancea completed his pediatric residency and cardiology subspecialty training at McGill University and the Montreal Children's Hospital (MCH). Along the way he also picked up a Physician Executive MBA (University of Tennessee). An accomplished interventional pediatric cardiologist (training at UCSF), Dr. Dancea has led his Division since 2009.
McGill researchers have identified two proteins that work together to drive neuroinflammation in acute conditions such as microbial or autoimmune encephalitis, and in chronic conditions such as multiple sclerosis.
A team of basic and clinical scientists led by the University of Montreal Hospital* Research Centre’s (CRCHUM) Dr. Nathalie Arbour has opened the door to significantly improved treatments for the symptoms of Multiple Sclerosis (MS). In a study selected as among the top 10% most interesting articles published in the Journal of Immunology, the team identifies the elevated presence in MS patients of a type of white blood cell (CD4 T cell) that expresses NKG2C, a highly-toxic molecule harmful to brain tissues.
